 |
Under the guidance of K. R. Ravishankar, Chairman and Managing Director since 2008, the company has posted strong growth. In 2010, SeQuent reported a turnover of `284 crore and a net profit of `37.4 crore. Ravishankar has over 19 years of experience in the pharmaceutical industry.
Since its inception in 2002, with multiple manufacturing facilities spread over India, Vietnam and Italy, SeQuent has carved a niche in the chemical and pharmaceutical industry with a stellar reputation for research capabilities, stringent quality standards and manufacturing flexibility. The company’s manufacturing facilities can handle a wide range of unit operations required for synthetic chemistry, fermentation and extraction.
The company’s range of services includes custom synthesis, contract research and the entire gamut of analytical services and regulatory affairs services. It claims to be the world’s largest producer of anthelmintics and holds the distinction of being among India’s largest Custom Research and Manufacturing Services. SeQuent also operates Galenica, a joint venture operation with Orffa B.V, which is among the world’s largest veterinary pharmaceutical marketing companies. To enhance its capacities and increase the product range, SeQuent has recently invested `150 crore in three new therapeutic segments.
Over the years, research and development have been the backbone of SeQuent and have contributed to the organisation acquiring a number of patents and extensive publications.
| < Prev | Next > |
|---|
